Levaquin Lawsuit Attorneys at Bernstein Liebhard LLP Look Ahead to Initial Status Conference in Federal Fluoroquinolone MDL

November 30, 2015 (PRLEAP.COM) Business News
November 30, 2015 - Hundreds of Levaquin lawsuits (http://www.levaquinlawsuitcenter.com/) and other legal claims involving fluoroquinolone antibiotics and peripheral neuropathy will soon begin moving forward in the U.S. District Court, District of Minnesota. According to a notice issued by the Court on November 6th, the proceeding's Initial Status Conference will be convened on Tuesday, December 8th, at 4:00 p.m. (In Re: Fluoroquinolone Products Liability Litigation MDL No. 2642)

"Our Firm has heard from numerous individuals who claim to have sustained serious nerve damage while using Levaquin, Cipro or Avelox. We are pleased that the federal litigation is about to get underway, and are looking forward to next week's conference in the District of Minnesota," says Sandy A. Liebhard LLP, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is offering free, no-obligation Levaquin lawsuit reviews to patients who were diagnosed with peripheral neuropathy that could be associated with the use of a fluoroquinolone antibiotic.

Fluoroquinolone Peripheral Neuropathy Litigation
Court documents indicate that at least 225 peripheral neuropathy lawsuits involving Levaquin and other fluoroquinolone antibiotics are currently pending in the District of Minnesota. Plaintiffs accuse the drug's manufacturers of failing to adequately warn doctors and patients about the potential for permanent nerve damage and peripheral neuropathy, and further contend that they may have avoided serious injury if adequate warnings had been provided.

Fluoroquinolone antibiotics, such as Levaquin, Cipro and Avelox, have been used to treat millions of people suffering from bacterial infections, including staph, pneumonia, urinary tract infections, E. coli and salmonella. The labeling for the entire class has included mention of peripheral neuropathy since 2004. However, in 2013, the U.S. Food & Drug Administration (FDA) ordered the drugs' manufacturers to modify their product labels to warn that this potentially debilitating complication may occur soon after treatment with a fluoroquinolone has been initiated, and may be permanent.

Individuals who were diagnosed with permanent peripheral neuropathy allegedly due to their use of a fluoroquinolone antibiotic may be entitled to compensation for medical bills, lost wages, pain and suffering, and more. To learn more about filing a Levaquin, Cipro or Avelox lawsuit, please visit Bernstein Liebhard LLP's website. Free, no-obligation legal consultations can also be obtained by calling 800-511-5092.


About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3.5 billion on behalf of our clients. The Firm was named by The National Law Journal to the Plaintiffs' Hot List, recognizing the top plaintiffs firms in the country, for 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list for a dozen consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2015 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP
info(at)consumerinjurylawyers(dot)com
http://www.levaquinlawsuitcenter.com/
https://plus.google.com/115936073311125306742?rel=author

Share Article